NCT01709435 2023-12-22Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid TumorsNational Cancer Institute (NCI)Phase 1 Completed41 enrolled 20 charts
NCT02709889 2020-10-19Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsAbbViePhase 1/2 Terminated200 enrolled 21 charts